Csajka C - Search Results

1

Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.

Gotta V, Widmer N, Decosterd LA, Chalandon Y, Heim D, Gregor M, Benz R, Leoncini-Franscini L, Baerlocher GM, Duchosal MA, Csajka C, Buclin T. Gotta V, et al. Among authors: csajka c. Cancer Chemother Pharmacol. 2014 Dec;74(6):1307-19. doi: 10.1007/s00280-014-2599-1. Epub 2014 Oct 9. Cancer Chemother Pharmacol. 2014. PMID: 25297989 Free article. Clinical Trial.

2

Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.

Csajka C, Buclin T, Brunner HR, Biollaz J. Csajka C, et al. Clin Pharmacokinet. 1997 Jan;32(1):1-29. doi: 10.2165/00003088-199732010-00001. Clin Pharmacokinet. 1997. PMID: 9012554 Review.

3

Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients.

Csajka C, Décosterd LA, Buclin T, Pagani JL, Fattinger K, Bille J, Biollaz J. Csajka C, et al. Eur J Clin Pharmacol. 2001 Dec;57(10):723-7. doi: 10.1007/s00228-001-0377-6. Eur J Clin Pharmacol. 2001. PMID: 11829202 Clinical Trial.

4

Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers.

Csajka C, Buclin T, Fattinger K, Brunner HR, Biollaz J. Csajka C, et al. Clin Pharmacokinet. 2002;41(2):137-52. doi: 10.2165/00003088-200241020-00005. Clin Pharmacokinet. 2002. PMID: 11888333

5

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.

Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T. Csajka C, et al. Clin Pharmacol Ther. 2003 Jan;73(1):20-30. doi: 10.1067/mcp.2003.22. Clin Pharmacol Ther. 2003. PMID: 12545140

6

Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.

Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, Stupp R. Ostermann S, et al. Among authors: csajka c. Clin Cancer Res. 2004 Jun 1;10(11):3728-36. doi: 10.1158/1078-0432.CCR-03-0807. Clin Cancer Res. 2004. PMID: 15173079

7

Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.

Csajka C, Marzolini C, Fattinger K, Décosterd LA, Telenti A, Biollaz J, Buclin T. Csajka C, et al. Antimicrob Agents Chemother. 2004 Sep;48(9):3226-32. doi: 10.1128/AAC.48.9.3226-3232.2004. Antimicrob Agents Chemother. 2004. PMID: 15328077 Free PMC article. Clinical Trial.

8

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.

Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A, Rochat B, Eap CB, Henry H, Biollaz J, Buclin T. Widmer N, et al. Among authors: csajka c. Br J Clin Pharmacol. 2006 Jul;62(1):97-112. doi: 10.1111/j.1365-2125.2006.02719.x. Br J Clin Pharmacol. 2006. PMID: 16842382 Free PMC article.

9

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.

Colombo S, Buclin T, Cavassini M, Décosterd LA, Telenti A, Biollaz J, Csajka C. Colombo S, et al. Among authors: csajka c. Antimicrob Agents Chemother. 2006 Nov;50(11):3801-8. doi: 10.1128/AAC.00098-06. Epub 2006 Aug 28. Antimicrob Agents Chemother. 2006. PMID: 16940065 Free PMC article.

10

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.

Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M, Csajka C, Biollaz J, Buclin T. Widmer N, et al. Among authors: csajka c. Br J Cancer. 2008 May 20;98(10):1633-40. doi: 10.1038/sj.bjc.6604355. Epub 2008 May 6. Br J Cancer. 2008. PMID: 18475296 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

157 results

Search Page